{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:17:19Z","timestamp":1778879839838,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2025.12.002","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:35:12Z","timestamp":1770150912000},"page":"289-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia"],"prefix":"10.1016","volume":"30","author":[{"given":"Yusuf","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Boursier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Arab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2025.12.002_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"Suppl","key":"10.1016\/j.cld.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.cld.2025.12.002_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","article-title":"Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver","volume":"10","author":"Kaya","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib7","first-page":"1413","article-title":"Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease","volume":"5","author":"Jiang","year":"2024","journal-title":"M\u00e9d Sur"},{"key":"10.1016\/j.cld.2025.12.002_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.cld.2025.12.002_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.cld.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib11","article-title":"New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: a longitudinal cohort study","author":"Kim","year":"2024","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cld.2025.12.002_bib12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4254\/wjh.v16.i6.871","article-title":"Sarcopenia and metabolic dysfunction associated steatotic liver disease: time to address both","volume":"16","author":"Wong","year":"2024","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib13","first-page":"2451","article-title":"The impact of population ageing: a review","volume":"50","author":"Ismail","year":"2021","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.cld.2025.12.002_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00004836-200304000-00015","article-title":"Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study","volume":"36","author":"S\u00f8rensen","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cld.2025.12.002_bib15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"173","author":"Thomas","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cld.2025.12.002_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.12.002_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14276","article-title":"Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies","volume":"54","author":"Zhou","year":"2024","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.cld.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.3390\/curroncol29070356","article-title":"Non-alcoholic fatty liver disease and extrahepatic cancers: a wolf in sheep\u2019s clothing?","volume":"29","author":"Mitsala","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cld.2025.12.002_bib20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.tem.2024.02.017","article-title":"Unveiling the cancer risk nexus of the steatotic liver","volume":"35","author":"Kim","year":"2024","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.cld.2025.12.002_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1609828","article-title":"The adipokine component in the molecular regulation of cancer cell survival, proliferation and metastasis","volume":"27","author":"Umar","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.cld.2025.12.002_bib22","first-page":"0","article-title":"Low-grade chronic inflammation: a shared mechanism for chronic diseases","volume":"40","author":"Cifuentes","year":"2025","journal-title":"Physiology (Bethesda)"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/MCG.0000000000000255","article-title":"Leaky gut, microbiota, and cancer: an incoming hypothesis","volume":"48","author":"Saggioro","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cld.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41419-023-06386-8","article-title":"Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21","volume":"15","author":"Sui","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cld.2025.12.002_bib25","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2022.37.e146","article-title":"A review of sarcopenia pathophysiology, diagnosis, treatment and future direction","volume":"37","author":"Cho","year":"2022","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.cld.2025.12.002_bib26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/jcsm.12447","article-title":"Is muscle failure a better term than sarcopenia?","volume":"10","author":"Suetta","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cld.2025.12.002_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078933","article-title":"Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis","volume":"14","author":"Deng","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.cld.2025.12.002_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101544","article-title":"Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"29","author":"Malik","year":"2024","journal-title":"Ann Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.cgh.2023.02.013","article-title":"Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis","volume":"21","author":"Harring","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib30","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"43","author":"Li","year":"2024","journal-title":"Clin Nutr"},{"issue":"11","key":"10.1016\/j.cld.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1002\/hep4.2061","article-title":"Sarcopenia, healthy living, and mortality in patients with chronic liver diseases","volume":"6","author":"Van Dongen","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1152\/physrev.00061.2017","article-title":"Sarcopenia: aging-related loss of muscle mass and function","volume":"99","author":"Larsson","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.cld.2025.12.002_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/sci6040059","article-title":"How sarcopenia, muscle mass, strength, and performance relate to non-alcoholic fatty liver disease: a systematic review","volume":"6","author":"Rigor","year":"2024","journal-title":"Sci"},{"key":"10.1016\/j.cld.2025.12.002_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6297651","article-title":"The common mechanisms of sarcopenia and NAFLD","volume":"2017","author":"Zhai","year":"2017","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.cld.2025.12.002_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13098-023-01022-z","article-title":"Causal relationship between insulin resistance and sarcopenia","volume":"15","author":"Liu","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.cld.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14218\/JCTH.2020.00065","article-title":"Skeletal muscle dysfunction in the development and progression of nonalcoholic fatty liver disease","volume":"8","author":"Altajar","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2020.06.003","article-title":"Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise","volume":"52","author":"Paris","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.cld.2025.12.002_bib38","article-title":"Myosteatosis: diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease","volume":"6","author":"Henin","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2025.12.002_bib39","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/jcsm.12784","article-title":"Understanding the gut microbiota and sarcopenia: a systematic review","volume":"12","author":"Liu","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cld.2025.12.002_bib40","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.3748\/wjg.v29.i27.4236","article-title":"Sarcopenia in cirrhosis: prospects for therapy targeted to gut microbiota","volume":"29","author":"Maslennikov","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2025.12.002_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8859719","article-title":"Nonalcoholic fatty liver disease and sarcopenia: where do we stand?","volume":"2020","author":"Mikolasevic","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afae090","article-title":"Sarcopenia prevalence using handgrip strength or chair stand performance in adults living with type 2 diabetes mellitus","volume":"53","author":"Belfield","year":"2024","journal-title":"Age Ageing"},{"key":"10.1016\/j.cld.2025.12.002_bib43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.cld.2025.12.002_bib44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/diagnostics14090899","article-title":"Reliability and agreement assessment of sarcopenia diagnosis through comparison of bioelectrical impedance analysis and dual-energy x-ray absorptiometry","volume":"14","author":"Lee","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cld.2025.12.002_bib45","first-page":"9630","article-title":"Impact of exercise training on the sarcopenia criteria in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"31","author":"Gonzalez","year":"2021","journal-title":"Eur J Transl Myol"},{"key":"10.1016\/j.cld.2025.12.002_bib46","doi-asserted-by":"crossref","first-page":"afac003","DOI":"10.1093\/ageing\/afac003","article-title":"Resistance exercise as a treatment for sarcopenia: prescription and delivery","volume":"51","author":"Hurst","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.cld.2025.12.002_bib47","doi-asserted-by":"crossref","first-page":"926","DOI":"10.14740\/jocmr2361w","article-title":"Nutrition for sarcopenia","volume":"7","author":"Yanai","year":"2015","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1016\/j.cld.2025.12.002_bib48","doi-asserted-by":"crossref","first-page":"102417","DOI":"10.1016\/j.jceh.2024.102417","article-title":"Branched-chain amino acid supplements for sarcopenia in Lliver cirrhosis: a systematic review and meta-analysis","volume":"15","author":"Abuelazm","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2025.12.002_bib49","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.3390\/ijms25084300","article-title":"Emerging therapeutic strategies in sarcopenia: an updated review on pathogenesis and treatment advances","volume":"25","author":"Najm","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:56:52Z","timestamp":1778878612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326125001047"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.002","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}